Anti-Carboxypeptidase A4 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the propeptide domain of human Carboxypeptidase A4, validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-
UniProt
Q9UI42
Size
100ug
Cat. #
RP3CarboxypeptidaseA4

In stock

SKU
RP-CarboxypeptidaseA4

Options

As low as: $130.00

Target Overview

Carboxypeptidase A4 (CPA4, UniProt Q9UI42) is a secreted metalloprotease belonging to the M14A family of zinc-dependent carboxypeptidases. The enzyme catalyzes the hydrolytic removal of hydrophobic C-terminal amino acid residues from peptide substrates, with demonstrated preference for phenylalanine, leucine, isoleucine, methionine, tyrosine, and valine. CPA4 is synthesized as a 421-amino-acid precursor and secreted into the extracellular space, where it is thought to participate in the local regulation of peptide hormone and neuropeptide activity through proteolytic processing. Unlike its pancreatic relatives CPA1 and CPA2, which function primarily in digestion, CPA4 is expressed broadly across human tissues and is increasingly recognized for its involvement in pathological processes. The enzyme has attracted attention in cancer biology, where elevated expression has been observed in multiple malignancies and associated with tumor aggressiveness and therapeutic resistance.

Background

CPA4 was originally described as a member of the carboxypeptidase A family but was distinguished from digestive carboxypeptidases by its widespread tissue expression and secreted, rather than intracellular, localization. Functional studies confirm that CPA4 cleaves peptides with bulky hydrophobic C-termini, a substrate specificity consistent with roles in modulating bioactive peptide signaling cascades. The enzyme requires zinc for catalytic activity and operates optimally under physiological pH conditions. Recent work has positioned CPA4 as a marker and potential mediator of cancer progression. Adeluola et al. recently reviewed its role across multiple tumor types, emphasizing correlations between CPA4 expression and aggressive phenotypes, including metastasis and drug resistance. Mendelian randomization studies have implicated CPA4 in hepatocellular carcinoma and lung squamous cell carcinoma, with genetic data suggesting causal relationships between circulating CPA4 levels and cancer risk. Beyond oncology, CPA4 has been examined in the context of genomic imprinting and epigenetic regulation, with altered methylation patterns noted in recurrent miscarriage and cancer cell lines. These emerging associations suggest that CPA4 may serve not only as a prognostic biomarker but also as a candidate for therapeutic intervention in malignancies where peptide signaling contributes to disease biology. Triple Point Biologics offers three rabbit polyclonal antibodies targeting the propeptide domain of CPA4, validated for use in Western blot, immunohistochemistry, and immunofluorescence applications with confirmed reactivity in human samples.

References

  1. Adeluola AA et al (2025) Carboxypeptidase A4: A Biomarker for Cancer Aggressiveness and Drug Resistance. Cancers (Basel). PubMed · DOI
  2. Chen X et al (2026) Integrating plasma proteomes with genome-wide association data for causal protein identification in hepatocellular carcinoma: A bidirectional Mendelian randomization study. Medicine (Baltimore). PubMed · DOI
  3. Cheng S et al (2025) Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma. Sci Rep. PubMed · DOI
  4. Niu Y et al (2025) Comprehensive analysis of DNA methylation patterns in recurrent miscarriage: imprinted/non-imprinted genes and their regulation across sperm and fetal-maternal tissues. PeerJ. PubMed · DOI
  5. Krushkal J et al (2025) Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies. Clin Epigenetics. PubMed · DOI

Additional Specifications

Size 100 µg
Gene Symbol CPA4
UniProt ID Q9UI42
Host Species Rabbit
Species Reactivity Validated- Human
Potential-
Pack Size 100ug
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 17-113.
Immunogen (Metalloproteinase domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 122-416.
Immunogen (Metalloproteinase domain)Synthetic peptide corresponding to the Metalloproteinase domain of human Carboxypeptidase-A4 (UniProt Q9UI42).
Alternate Names CPA4, Carboxypeptidase A3, EC 3.4.17.-

Frequently Asked Questions

What molecular weight band should I expect for CPA4 on Western blot?

CPA4 is synthesized as a 421-amino-acid precursor with a predicted molecular weight of approximately 47 kDa. On reducing Western blots, you should expect a band near this size from cell lysates or conditioned media. Because CPA4 is a secreted metalloprotease that may undergo post-translational modification including glycosylation, the apparent molecular weight can shift slightly upward, sometimes appearing between 47-52 kDa depending on the tissue or cell type. If you observe additional lower bands, consider the possibility of proteolytic processing or degradation during sample preparation.

Does this antibody detect CPA4 in mouse or rat samples?

This antibody has been validated against human CPA4. Cross-reactivity with mouse or rat CPA4 has not been formally validated. Human CPA4 shares approximately 80-85 percent sequence identity with mouse and rat orthologs, so cross-reactivity is possible but not guaranteed. If you are working with rodent samples, we recommend testing the antibody at the standard dilution first on a positive control lysate known to express CPA4, then titrating as needed. Include a CPA4-knockout or knockdown control if available to confirm band specificity.

What is the recommended starting dilution for Western blot with this CPA4 antibody?

Start at 1:1000 dilution in your blocking buffer for Western blot applications. This dilution has been validated with standard chemiluminescent detection systems. If your CPA4 expression level is low or you are working with conditioned media rather than whole-cell lysates, you may need to increase antibody concentration to 1:500. Conversely, if background is high, titrate to 1:2000 or 1:3000. Load 20-40 micrograms of total protein per lane as a starting point and include a recombinant CPA4 positive control if signal is weak.

Can I use this antibody for immunohistochemistry on formalin-fixed tissue?

Yes, This antibody is validated for Western blot; immunohistochemistry/immunofluorescence validation is in progress. For formalin-fixed paraffin-embedded tissue, antigen retrieval is typically required. Citrate buffer (pH 6.0) heat-induced epitope retrieval is a standard starting point for carboxypeptidase antibodies. Use the antibody at a dilution range of 1:50 to 1:200 depending on your detection system and tissue type. Because CPA4 is a secreted protein, staining may appear in the extracellular space and cytoplasm rather than being strictly intracellular. Include a CPA4-negative tissue as a specificity control.

What tissues or cell lines are good positive controls for CPA4 expression?

CPA4 is broadly expressed across human tissues, with relatively high levels reported in prostate, brain, kidney, and certain tumor types. For Western blot positive controls, prostate cancer cell lines such as PC-3 or DU145 are reasonable starting points, as CPA4 has been implicated in prostate biology. Alternatively, normal human kidney or brain lysates can serve as positive controls. If you are studying a specific tissue context, check public expression databases like the Human Protein Atlas or GEO to identify cell lines or tissues with robust CPA4 mRNA and protein expression.

Is CPA4 intracellular or secreted, and how should I prepare samples?

CPA4 is a secreted metalloprotease. It is synthesized with a signal peptide and released into the extracellular space. For Western blot, you can detect CPA4 in whole-cell lysates, but signal may be stronger in conditioned culture media or serum samples. If analyzing conditioned media, concentrate samples by precipitation or ultrafiltration before loading to improve sensitivity. Use protease inhibitor cocktails during lysis to prevent degradation, and include EDTA-free inhibitors if you plan downstream enzymatic assays, since CPA4 is a zinc-dependent enzyme that may be inhibited by metal chelators.

Are there CPA4 isoforms or splice variants I should be aware of?

The primary CPA4 transcript encodes the 421-amino-acid precursor. Alternative splice variants have been reported in sequence databases, but the functional significance and expression levels of these isoforms are not well characterized. The canonical isoform is most commonly studied and is the expected target of this antibody. If you observe multiple bands on Western blot that do not correspond to post-translational modifications, consider the possibility of splice variants or proteolytic fragments. Sequence the band by mass spectrometry if isoform distinction is critical to your experiment.

How should I store this antibody and what is the shelf life?

Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The antibody is supplied at 100 micrograms and is stable for at least 12 months from date of receipt when stored properly. For short-term use, an aliquot can be kept at 4°C for up to one month. Avoid prolonged exposure to room temperature. If you observe particulates after thawing, centrifuge briefly before use. Adding sodium azide (0.02-0.05 percent final concentration) or glycerol (50 percent) can extend stability for long-term storage at -20°C or 4°C, respectively.

Validation imagery coming soon

Western blot validation figures for RP-CarboxypeptidaseA4 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • CPA4
  • Carboxypeptidase A3
  • EC 3.4.17.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →